In the News

Salutaris Medical Devices Announces Launch of Clinical Trial

Salutaris Medical Devices, Inc. today announced the start of a clinical trial investigating the use of its ophthalmic brachytherapy device to treat neovascular Age-related Macular Degeneration (nAMD).

Continue reading →


Salutaris Medical Devices Receives 510(k) Clearance from U.S. FDA for 
SMD-Sr90-DA Radionuclide Brachytherapy Source

Salutaris Medical Devices, Inc. (SalutarisMD®) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their
SMD-Sr90-DA™ Radionuclide Brachytherapy Source (RBS). The SMD-Sr90-DA™ RBS device is indicated for episcleral brachytherapy. The device is intended for use within a manual brachytherapy applicator system.

Continue reading →


Salutaris Medical Devices Achieves ISO 13485 Certification

Today, Salutaris Medical Devices, Inc. (SalutarisMD®) announced it has received ISO 13485:2003 certification, an internationally recognized standard for medical device quality systems, marking completion of a critical step in efforts towards commercialization of the SalutarisMD technology for the treatment of wet age-related macular degeneration (wet AMD).

Continue reading →


SalutarisMD to Introduce its New Generation Medical Device for wet AMD Therapy at Ophthalmology Futures European Forum

Today, Salutaris Medical Devices (SalutarisMD®) announced that during its upcoming presentation at the Ophthalmology Futures European Forum on September 8, the Company will introduce its new generation, commercial ready, episcleral brachytherapy applicator system.

Continue reading →


Salutaris Medical Devices™ Winner of Arizona Innovation Challenge

Salutaris Medical Devices, Inc. (SalutarisMD®) is pleased to report that we are a winner of the Arizona Innovation Challenge (AIC).

Continue reading →


Salutaris Medical Devices™ Wet AMD Distance of Choroid Study Presented at ARVO 2016

Today results from the Salutaris Medical Devices, Inc. (SalutarisMD®) wet age-related Macular Degeneration (wet AMD) Distance of Choroid Study (DOCS) were featured in two presentations at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) Annual Meeting.

Continue reading →


EyewireToday

Hoya Group Invests in SalutarisMD Wet AMD Therapy Technology

HOYA Group announced today that it has closed financing in Salutaris Medical Devices (SalutarisMD®). SalutarisMD will use the funding to further its growth strategy in developing its patented medical device designed for minimally invasive therapy of wet age-related macular degeneration (wet AMD).

Continue reading at EyewireToday →


Salutaris Medical Devices Announces 510(k) Clearance BARCELONA, Spain (September 3, 2015) – At Ophthalmology Futures European Forum 2015, Salutaris Medical Devices (SalutarisMD®) announced that its SMD Sr90-1 Radionuclide Brachytherapy Source (RBS) received 510(k) clearance from the U.S. Food and Drug …


SalutarisMD Wet AMD Choroidal Distance Study Results Previewed at Ophthalmology Futures Forum Europe 2014

At the Ophthalmology Futures Forum Europe 2014 today, initial results were previewed from a Salutaris Medical Devices, Ltd. (SalutarisMD®) sponsored observational study conducted at Moorfields Eye Hospital NHS Foundation Trust. This study is a forerunner to upcoming multi-center interventional studies to be led by Moorfields.

Continue reading →


SalutarisMD Wet AMD Choroidal Distance Study Initiated LONDON, UK (February 24, 2014) – Enrolment has begun in a Salutaris Medical Devices, Ltd. (SalutarisMD®) sponsored observational study conducted at Moorfields Eye Hospital NHS Foundation Trust. In 2013, Moorfields and SalutarisMD announced …


SalutarisMD Wet AMD Treatment – Long Term Positive Outcomes Presented at Ophthalmology Futures Forum AMSTERDAM, Netherlands (October 4, 2013) – At the Ophthalmology Futures European Forum yesterday, results were presented from a cohort study evaluating the use of a minimally …


SalutarisMD Data for Wet AMD Treatment with Long Term Positive Outcomes Presented at The Royal College of Ophthalmologists Annual CongressO LIVERPOOL, England (May 22, 2013)—At The Royal College of Ophthalmologists Annual Congress yesterday, results were presented from a cohort study …


As Seen In The Wall Street Journal

SalutarisMD Presents Data for Wet AMD Treatment with Long Term Positive Outcomes at ARVO

At the Association for Research in Vision and Ophthalmology, Inc. (ARVO) Annual Meeting yesterday, Kamaljit Balaggan, BSc (Hons), MBBS, MRCOphth, PhD, Vitreoretinal Surgery Fellow at Moorfields Eye Hospital National Health Service (NHS) Foundation Trust in London, presented results from a cohort study evaluating the use of a minimally invasive retrobulbar episcleral brachytherapy device developed by Salutaris Medical Devices (SalutarisMD(TM)) to treat Wet AMD (Age-related Macular Degeneration), the leading cause of vision loss and blindness.

Continue reading →


Moorfields Eye Hospital

Moorfields Eye Hospital Announces Vision Research Collaboration on Novel Treatment for Wet Age-related Macular Degeneration

Moorfields Eye Hospital is to collaborate with Salutaris Medical Devices, Ltd (SalutarisMD™) to advance the research and development of a novel medical device for use in the treatment of wet age-related macular degeneration (AMD). The device enables retinal specialists to administer high precision localised radiation therapy to the back of a patient’s eyes to stem vision loss.

Continue reading at Moorfields →


BIOOPTICS WORLD

SalutarisMD Presents Data for Promising Device to
Treat Wet AMD at ASTRO Annual Meeting

At the American Society of Radiation Oncology (ASTRO) Annual Meeting yesterday, Baldassarre Stea, MD, PhD, Professor and Head, University of Arizona Department of Radiation Oncology and The University of Arizona Cancer Center, presented results from a cohort study evaluating use of a minimally invasive retrobulbar episcleral brachytherapy device developed by Salutaris Medical Devices (SalutarisMD™) to treat wet AMD (age-related macular degeneration), the leading cause of vision loss and blindness.

Continue reading at BioOptics World →


As Seen In Wall Street Journal’s MarketWatch

SalutarisMD Announces Positive Case Report of a New Investigational Wet AMD Therapy at ARVO

Positive results from a trial of episcleral brachytherapy to treat wet age-related macular degeneration (wet AMD) were presented today at the ARVO Drug and Gene Delivery to the Back of the Eye Conference. The case reported was drawn from a Phase 1 study to assess the safety of this new investigational therapy for the leading cause of vision loss and blindness. Salutaris Medical Devices, Inc. (SalutarisMD™) developed the device and sponsored the study.

Continue reading →


Wall Street Journal’s MarketWatch

SalutarisMD Presents Dosimetry Data for Promising
Device to Treat Leading Cause of Blindness at AAPM Annual Meeting

At the American Association of Physicists in Medicine (AAPM) Annual Meeting yesterday, Russell J. Hamilton, PhD, Professor and Physics Section Head, University of Arizona Department of Radiation Oncology, reviewed dosimetry data for a minimally invasive episcleral brachytherapy device developed by Salutaris Medical Devices, Inc. (SalutarisMD™) to treat Wet AMD (Age-related Macular Degeneration), the leading cause of vision loss and blindness.

Continue reading →


AS SEEN IN OCULAR SURGERY NEWS

Episcleral brachytherapy may present minimally invasive treatment option for AMD

Episcleral brachytherapy safely treated choroidal neovascularization in a phase 1 clinical study, the trial’s lead investigator said here. Reid Schindler, MD, presented results at Retina 2012 from a 90-day study of six patients with classic or occult neovascular lesions who were treated with non-invasive episcleral brachytherapy. In episcleral brachytherapy, using indirect ophthalmoscopy to view the macula, the surgeon places a transilluminated probe behind the posterior sclera and applies 24 Gy of radiation.

Continue reading →


As Seen In Wall Street Journal’s MarketWatch

SalutarisMD Announces Positive Study Results for a New Investigational Wet AMD Therapy

At Retina Meeting 2012 today, Reid Schindler, M.D., presented positive Phase I data from a human study designed to assess a new investigational therapy to treat Wet Age-related Macular Degeneration (Wet AMD), the leading cause of vision loss and blindness. Salutaris Medical Devices, Inc. (SalutarisMD™) developed the minimally invasive device and sponsored the study.

Continue reading →